LMRI earnings analysis
What we found in LMRI's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Lumexa Imaging generated $264.162 million of revenue, 4.4% above the prior quarter and approximately 0.4% above consensus, but GAAP diluted EPS of $0.03 missed the $0.12 estimate. Management reiterated full-year revenue and Adjusted EPS guidance and narrowed the Adjusted EBITDA range around an unchanged $238 million midpoint. The quarter also highlighted substantial execution and reporting risks: five material weaknesses remained unremediated as of June 30, 2026, while a 1% increase in adjusted SOFR would add approximately $8.2 million to annual interest expense.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew sequentially and beat estimates
- Revenue was $264.162 million, up 4.4% from $253 million in 2026 Q1 and approximately 0.4% above the $263.138 million consensus estimate.
- Returned to GAAP profitability
- GAAP diluted EPS was $0.03 versus $0.02 in 2026 Q1, indicating a return to profitability, but it was $0.09 below the $0.12 consensus estimate.
- Full-year outlook was reiterated
- Management reiterated full-year revenue guidance of $1.045 billion-$1.097 billion and Adjusted EPS guidance of $0.71-$0.77.
- EBITDA range narrowed around same midpoint
- Adjusted EBITDA guidance was narrowed to $235 million-$241 million from $234 million-$242 million, while the midpoint remained $238 million.
- New finance platform implemented
- The company implemented a new general ledger and consolidation platform during the quarter ended June 30, 2026, as part of its remediation plan.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Five material weaknesses remain open
- Management concluded disclosure controls were not effective as of June 30, 2026. Five material weaknesses remained unremediated, including deficiencies in the control environment, risk assessment, revenue accounting, segregation of duties, and IT general controls.
- Variable-rate debt creates earnings sensitivity
- A hypothetical 1% increase in adjusted SOFR under the Refinancing Term Loan would increase annual interest expense by approximately $8.2 million and reduce income before taxes by the same amount.
- Financial reporting misstatement risk
- The company states that its control weaknesses could result in a misstatement of substantially all account balances or disclosures, and prior weaknesses resulted in a restatement of previously issued financial statements and other audit adjustments that were immaterial.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.03
What they said about what is next.
The filing excerpt does not provide new quantitative guidance. The August 12, 2026 earnings update reiterated full-year revenue guidance of $1.045 billion-$1.097 billion and Adjusted EPS guidance of $0.71-$0.77; Adjusted EBITDA guidance was narrowed to $235 million-$241 million, with the $238 million midpoint unchanged.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- In the Q1 2026 10-Q filing, Lumexa Imaging reported revenues of $267.73 million, representing a 3.8% increase year-over-year. However, the company posted a net loss per share (EPS) of -$0.20, which fell significantly…
- 10-K · March 30, 2026
- Lumexa Imaging positions itself as a scaled national IDTF platform focused on advanced imaging (MRI/CT) with a 188-center footprint across 13 states and a referral network of ~102,000 physicians. Management highlights…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LMRI makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever